ArticleFrontiers in pharmacology2025
Pharmacokinetic-pharmacodynamic target attainment analyses as support for meropenem dosing regimens in critically ill adult and elderly patients with
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Critically ill patients often undergo profound pathophysiological changes that alter the pharmacokinetics (PK) of hydrophilic antibiotics such as meropenem. These changes, combined with bacterial susceptibility, may reduce antimicrobial efficacy. This study aimed to optimize meropenem dosing regimens for adult and elderly critically ill patients with Pseudomonas aeruginosa infections using a model-informed approach. Methods: Limited PK sampling and therapeutic drug monitoring (TDM) data were analyzed to develop a population PK model. Covariates were evaluated, and Monte Carlo simulations (n = 1,000 virtual patients) were conducted to assess alternative dosing strategies, including 0.75-3 g/day (0.5 h infusion) and 0.5-1.5 g every 6-8 h. Probabilities of target attainment (PTA; 40% fT > MIC ×4 and 100% fT > MIC ×4) and cumulative fraction of response (CFR) were calculated. Results: A one-compartment model with age-adjusted distribution volume best described the data. Population PK estimates were 4.68 L/h for clearance and 4.47 L for distribution volume, both with <50% variability. Age was a significant covariate, with Vd increasing progressively with advancing age. Simulations showed that 750 mg loading followed by 500 mg every 6 h achieved ≥90% CFR in 90-year-old patients, whereas 1 g loading plus 3 g/day (four times daily) was optimal for 40-60-year-old adults. Conclusions: Age-related increases in meropenem distribution volume necessitate tailored dosing regimens in critically ill patients. More frequent administration (q6h) improved CFR, particularly in elderly populations. Model-informed precision dosing may enhance treatment success against P. aeruginosa infections in intensive care settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.